CENTRE FOR DOCTORAL TRAINING IN THE EPSRC CENTRE FOR INNOVATIVE MANUFACTURING IN EMERGENT MACROMOLECULAR THERAPIES

拟议的EPSRC CDT的重点将是英国以生物为中心的制药和医疗保健生物技术行业发展最快的部分所需的制造研究和培训，这些领域对未来的医学具有重大影响。生物加工工业制造新型大分子药物蛋白质，以治疗一系列慢性和衰弱的人类疾病。英国凭借其科学基础处于领先地位，并拥有支撑该领域的独特大学能力。虽然收入巨大，2009年全球约1100亿GB，但如果要满足降低成本和最大限度减少浪费的需求，该行业面临着巨大的变革压力，人们将受益于可获得的强效药物。如果现代药物的潜力要通过广泛的分销来实现，那么在接下来的十年里，制造业将需要发生翻天覆地的变化。此外，这是一个被广泛接受的技能短缺的个人，拥有该行业所需的制造研究培训。加入EPSRC紧急大分子疗法创新制造中心将通过培训下一代高技能和有才华的生物工艺制造研究人员来提高国家能力。我们的目标是培养未来的生物过程工程领导者，他们将以负担得起的成本将新的科学进步转化为安全生产的、更具选择性的治疗方法，用于目前难以治愈的疾病。为了实现这一目标，我们将把CDT博士嵌入到英国顶尖机构和EPSRC新兴大分子疗法创新制造中心充满活力的研究社区中，以确保他们在影响和知识转移方面受益于研究主导的公司。这些协作的实施将使CDT能够在利用卓越研究成果的培训环境中探索新的和新兴的想法，并在中心研究方案之间产生强大的协同作用。

The focus of the proposed EPSRC CDT will be on manufacturing research and training required in the most rapidlydeveloping parts of the UK bio-centred pharmaceutical and healthcare biotechnology sector, that have major implicationsfor future medicine. The bioprocess industry manufactures novel macromolecular drugs, proteins, to address a broad rangeof chronic and debilitating human diseases. The UK holds a leading position by virtue of its science base and has unique university capabilities underpinning the sector. Whilst revenues are large, ~£110bn in 2009 on a worldwide basis, there arehuge pressures on the industry for change if demands for cost reduction and waste minimisation are to be met, andpopulations are to benefit from the potent drugs becoming available. A sea change in manufacturing will be needed overthe next decade if the potential of modern drugs are to make their way through to widespread distribution. Moreover this isa widely accepted skills shortage of individuals with the manufacturing research training needed for the sector.Alignment to the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies will deliver increasednational capability through training of the next generation of highly skilled and talented bioprocess manufacturingresearchers. Our aim is to train bioprocess engineering leaders of the future who will underpin translation of new scientificadvances into safely produced, more selective, therapies for currently intractable conditions at affordable costs. To achievethis we will embed CDT PhDs within the vibrant research community of the top UK Institutions and that of the EPSRCCentre for Innovative Manufacturing in Emergent Macromolecular Therapies, to ensure that they benefit in terms of impactand knowledge transfer from the links to research led companies. The gearing in of these collaborations will enable theCDT to explore new and emerging ideas in a training environment that draws on research excellence and to create strongsynergy between the Centre research programmes.